7884 Report 2010 Report 2010 02 06 2010 17:38 Page 08 08 Business review BTG plc Annual Report and Accounts 2010 Chairmans statement Our strategy is delivering Our business is robust Since our last annual report to shareholders We have made the decision to take Varisolve forward ourselves.
Completing the development of Varisolve and we have made good progress towards achieving marketing it in the US reimbursed sector is a big investment our near-term objectives, while positioning for BTG.
It is also an investment that has the potential to the business to deliver sustainable growth over deliver significant returns and is, we believe, in the best the long term.
We have almost completed the integration of the Protherics In addition to Varisolve, our pipeline comprises another business, which we acquired in December 2008.
The financial programme we intend to take to market ourselves, which benets of the acquisition are evident in our strong results for is Voraxaze, for methotrexate toxicity, and four other the year.
programmes we intend to partner.
Further details are provided in the CEOs review on pages 10 to 12 and in the Revenue of 98.5m 08 09: 84.8m generated a gross profit pipeline update on pages 17 and 18. of 65.7m 08 09: 47.7m.
The Group made a profit before tax of 9.1m, which compares with a loss before tax of 11.3m I wish to thank the executives, management and employees in the prior year.
Cash and equivalents increased to 82.6m of BTG for another year of hard work and progress across at 31 March 2010 from 78.2m at 31 March 2009. the business.
I am grateful to my Board colleagues for their continued guidance and in particular, to Professor Colin The financial review on pages 18 to 21 describes the results Blakemore, who will retire from the Board at this years Annual for the year in detail and provides a financial outlook for the General Meeting in July, for his significant contributions to the year ahead.
companys development during his three years as a director.
I would also like to thank our shareholders for their continued A key objective for the past year was the establishment support of our strategy and team.
of a sales and marketing capability in the US, which is core to our growth strategy.
I am pleased to report that we have We look forward with excitement and confidence to the now put in place the key commercial operations required year ahead, in which we start selling our own products to enable us to begin marketing our own products in the US.
in the US and take the next step towards becoming a sustainably profitable specialty pharmaceuticals business.
From October 2010, when the current distribution agreement ends, we will start selling our two approved products, Dr John Brown CroFab, an anti-venom, and DigiFab, for digoxin toxicity, Chairman in the US ourselves.
These established, potentially life-saving products have limited competition and are well known by the specialists who administer them.
These attributes make them ideal first products for our new US sales and marketing teams.
To deliver sustainable growth we must add products both to our development pipeline and to our marketed products portfolio.
To this end, we continue to invest in our pipeline and to review suitable in-licensing and acquisition opportunities: for the latter, having a US sales capability increases our attractiveness as a partner.
7884 Report 2010 Report 2010 02 06 2010 17:38 Page 09 09 Business review BTG plc Annual Report and Accounts 2010 These strong results show the strength of our business model.
We look to the future with confidence.
